commercial XPHOZAH. for Thank today great It you, discuss to here be performance Mike. IBSRELA to and the is
for patient support the path to both deemed and approach define a products, access be that option options treatment our favorable response to inadequate. targeting affordability authorization enabling treatment driving their novel high-volume in patients Our programs. as patient commercial the existing with policies first-in-class of support is And and writers our of performance coverage areas, need to access prior centers of execution identification strong in which reflects disruptive on disease
Let with IBSRELA. me begin
need clinical seeing of to access, identifying path their the response IBSRELA's of treatment Our by on increasingly HCPs driven of the IBSRELA. IBS-C and treatment this driving confidence HCPs confidence Based the that now evolving in have launch option. fundamentals their are performance. are the expanded following practice is for in favorable treatment in strength they patients are product they patients a the novel options
first saw parameters new refill writers product, growth across the well prescriptions. for and in we repeat prescriptions in including During key quarter, as demand all and growth increases new the writers as
We of seasonality metrics resets demand growth across these encouraged key to by first insurance industry commonly being IBSRELA impacted is by the that very renewal authorization are linked the continued quarter prior and seen plan despite processes.
attracting force quarter, XX from motivated market We and strong to to with enthusiastic experienced IBSRELA the job a sales territories. IBSRELA who During disrupting join process team part innovative of first the the GI and began be extensive IBS-C experience to the sales the footprint XXX we expand with an territories dedicated posting, response are to the talent therapy. sales
of continuously are in deployment have to This end seen team our strong on well us quarter. to targets base puts are capitalize the of further full as on HCP writers new sales we footprint force the across completed and to training the broadening second of sensitivity a who drive is view writer promotion be track IBSRELA. candidates their expanded Hiring, high-riding in this use patients who across increases by our growing drive for position as
strong, fundamental expectations performance our stated with XXXX quarter-over-quarter we The consistent guidance. are continued the IBSRELA and anticipate for behind drivers our growth with
to Turning XPHOZAH.
We phosphorus not nephrology that to or phosphate to were been option need when tolerated. new have are their well of binders extremely manage insufficient absorption first-in-class with clear inhibitor. the patients community's It a response this pleased in is
into their pleased clinical this mechanism and clinical coverage their regimen patients. messaging defined nephrology dedicated to XPHOZAH. driving encouraged profile product favorably speaker increasingly mechanism blocking of blocking for integrating team, are Nephrologists data with uptake by promotional and are programs, and initiatives comprehensive blocking sales and therapeutic novel the the early interest responding are the campaign, Our experience, early novel and high omnichannel policies
physicians have target improvement are being we are that the seeing reflecting many serum ranges, is that receive of of that field phosphorus from and consistent XPHOZAH regularly in patients, feedback are been treated their these outside levels The continuously maintained. whom levels
add profile the treatment in Where regimen. dosing favorably We and or are they patient's patients adapting add regimen can and add the they binder and the of needs adopting they discontinue that patients existing patient's the reduce based that XPHOZAH are flexibility XPHOZAH or have HCPs the hearing to the with XPHOZAH can HCPs are patient's fully regimen adapting and also to regimen. the pleased can regimens patients. are responding XPHOZAH they the binder on are binder
We seeing are performance are for pleased the million in sales the uptick quarter. during consistent first indicators field. very XPHOZAH with This the with we $XX.X the we reported in is
patients highly us patients benefit with engaged Our from of sales many therapy, about outside have they are believe who eager force HCPs Nephrology therapy. identifying binders they ranges experiencing to may treatment XPHOZAH. target of with discussions our target rapidly are meaningful HCPs who can are to that despite intolerant reporting or learn is binders
are by patients that inadequately seeing with authorization binders fact seeing patients to experience. prior are please that with responding our has patients the therapy. to when Coverage to meeting HCPs the submitted are patient the been to authorizations attesting defined being unable responding path treatment criteria, for are treated or are response are to the are the favorably and XPHOZAH. access tolerate the prior HCPs a they access that policies and clinical outline gaining
them. well favorably Nephrology available as HCPs with Assist enable specialty to patient engagement our patient as staff office through and network that Ardelyx distribution responding authorization the offering, are affordability patient to further support access to programs prior services their our comprehensive and pharmacy
currently by who According XPHOZAH hyperphosphatemia internal tracking dynamics of launch therapy. research available Our to supported XXXX external metrics all own over launch report the are Spirox, is nephrologists, an the advance nearly conducted XX as rate the by surveyed April XPHOZAH. of XX%
satisfaction In satisfaction is addition, XX% nephrologists with and of demonstrates the and is treatment. high XX% among awareness interest research among to adopt reported intent treatment report the and high surveyed using XPHOZAH the that with again, those, nephrology is high users. community The of
to of need nephrology of our on build despite launch these momentum, continue a of will to patients. their option XPHOZAH treatment the in capitalizing treatment intent patients with We new and number that for upon the binders awareness adopt high are
Our is working. go-to-market strategy
strong mechanism could are responding gaining to and and a that coverage to profile. identifying nephrology from offices HCPs clinical treatment. novel policies presence data They patients responding country established favorably the and in benefit with therapy place, are have blocking patients and in across are XPHOZAH favorably the access We
pleased focus on and continuing with our performance this momentum. far We growth are thus the
and where community we'll I XPHOZAH, several we in as have ahead We our months to and key more will our forward look to the with the across you connect prescribing patients. commercial presence the relationship updates annual IBSRELA opportunity exciting clinical strong have continuing share present products, have future. for and with deepen data both with conferences to on trial medical clinical
With it Justin. that, to will I hand
